Chapter 12 - the patent tied to grace’s blood
Aureline’s patent described a naturally occurring variation affecting how certain fetal cells responded to oxygen and inflammation.
The language was technical, but the central claim was simple.
Brian believed the variation could make regenerative treatments more effective.
He needed proof that a child carrying it could survive controlled placental stress and show a measurable newborn response.
Grace carried the marker.
So did Melissa.
“How did he know?” Melissa asked.
Mara found the answer inside Brian’s files.
Years earlier, before they married, Melissa participated in a public ancestry and health-screening program. Brian’s company purchased anonymized datasets from a data broker.
He identified her record through personal details after they began dating.
He had known about the marker before proposing.
The relationship may have contained genuine affection.
It also contained selection.
Melissa read Brian’s earliest private note:
Candidate displays target variation, suitable age, limited close family oversight, high trust response.
The date was three weeks after their first meeting.
She placed the page down.
He had studied her the way he later studied her pregnancy.
“Did he marry me for this?”
Mara refused to invent certainty.
“We know the marker influenced his decisions. We cannot measure every feeling he had.”
Melissa appreciated the distinction.
Brian’s crimes did not require her entire marriage to have been false.
Some memories might have been real to her and useful to him at the same time.
The patent attempted to claim methods involving cells with the variation, not ownership of Grace herself.
Still, Brian’s acquisition proposal described “exclusive neonatal source access.”
He planned to store Grace’s cord blood and placental tissue under Aureline’s control.
EverVale’s collection contracts assigned all resulting commercial rights to the company.
The forged consent forms included Melissa’s supposed agreement.
Grace’s body had been built into a corporate transaction before birth.
Mara contacted the patent authorities and regulators. Aureline’s claims were suspended pending investigation. All biological samples collected from Melissa’s prior appointments were seized.
Brian had retained blood tubes from early pregnancy without permission.
No samples had been sold yet.
The potential acquisition collapsed.
Investors withdrew.
Aureline entered court-supervised closure.
Melissa asked that any legitimate future research involving the marker require independent consent and benefit patients rather than private secrecy.
She did not want Brian’s abuse to make all science feel dangerous.
She wanted the difference between research and exploitation made visible.
Research explained purpose.
Research allowed refusal.
Research monitored harm.
Brian had done none of those things.
Grace moved from intensive care into a step-down nursery.
Melissa began walking short distances.
Her medical team expected a long recovery but no immediate organ failure.
The placenta had suffered extensive damage. Pathologists found chemical deposits consistent with repeated AR-7 exposure.
They also found tiny healed puncture patterns in Melissa’s abdominal tissue.
She remembered Brian giving her injections near her hip, never her abdomen.
Then another memory returned.
During the second trimester, Brian applied numbing cream near her stomach before using what he called a glucose-monitoring patch.
She had felt a brief sting beneath it.
The patch contained micro-needles.
He delivered compounds while pretending to track blood sugar.
Every device he gave her had served another purpose.
Mara presented the evidence at Brian’s preliminary hearing.
He listened without visible emotion until the prosecution described the ancestry database.
His attorney objected to the characterization that he “selected” Melissa.
Brian whispered something urgently.
The attorney requested a recess.
Later, Brian offered to surrender all research claims in exchange for reducing the attempted-murder charge.
Prosecutors refused.
Patents were not compensation for poisoning.
Before leaving court, Brian sent one final legal message:
The marker did not originate with Melissa. Check the fertility clinic’s embryo records.
Melissa stared at the sentence.
She and Brian had conceived naturally—or so she believed.
They had visited a fertility clinic for testing after the earlier miscarriage but were told no treatment was necessary.
May you like
Brian now implied he had altered something before pregnancy.
👉 The genetic marker had led investigators backward from Grace’s blood to a clinic visit Melissa thought had changed nothing.
